Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 3, 2004, Pages 349-358

  Chiba, N ^a,b   Veldhuyzen Van Zanten, S J O ^c   Escobedo, S ^d   Grace, E ^b   Lee, J ^d   Sinclair, P ^e   Barkun, A ^f   Armstrong, D ^b   Thomson, A B R ^g  

^a Surrey GI Clinic   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d ASTRAZENECA   (United Kingdom)

^e INSINConsulting   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DYSPEPSIA; ECONOMIC EVALUATION; FEMALE; GENERAL PRACTICE; HEALTH CARE COST; HUMAN; LABORATORY TEST; MALE; MEDICAL INFORMATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES;

EID: 1342289013     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01865.x     Document Type: Article

References (33)

1. Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996; 10: 83-9.
2. Chiba N, Bernard L, O'Brien BJ, Goeree R, Hunt RH. A Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998; 12: 83-90.
3. Chiba N. Definitions of dyspepsia: time for a reappraisal. Eur J Surg Suppl 1998; 164: 14-23.
4. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000; 162(Suppl. 12): S3-23.
5. Delaney B, Moayyedi P, Deeks J, et al. The management of dyspepsia: a systematic review. Health Technol Assess 2000; 4: 1-189.
6. Tytgat GN. GERD remains an intriguing enigma. Gastroenterology 2001; 120: 787.
7. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. 2): II37-42.
8. Chiba N, van zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. Br Med J 2002; 324: 1012-6.
9. Hunt RH, Fallone CA, Thomson AB. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol 1999; 13: 213-7.
10. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
11. SM International Update Conference on Helicobacter pylori. Gastroenterology 1997; 113: S4-8.
12. Mock T, Yatscoff R, Foster R, et al. Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of Helicobacter pylori infection. Clin Biochem 1999; 32: 59-63.
13. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Cost Benefit Analysis. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford Medical Publications, Oxford University Press, Inc. 1997: 205-31.
14. Labour force and unpaid work of Canadians: selected labour force, demographic, cultural, educational and income characteristics by sex (based on the 1991 standard occupational classification) for Canadian provinces, territories and CMAs, 1996 census (20% sample data). Ottawa: Statistics Canada, 1996.
15. Grossman M. Human capital approach. In: Culyer AJ, Newhouse JP, eds. Handbook of Health Economics. Amsterdam: Elsevier, 2000: 349-108.
16. Vinod HD. Bootstrap methods: applications in econometrics. In: Maddala GS, Rao CR, Vinod HD, eds. Handbook of Statistics 11: Econometrics. New York: North-Holland, Elsevier Science, 1993: 629-61.
17. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19: 3219-36.
18. Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat Med 2001; 20: 1563-74.
19. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377-101.
20. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7: 723-40.
21. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623-30.
22. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000; 356: 455-60.
23. Heaney A, Collins JS, Watson RG, McFarland RJ, Bamford KB, Tham TC. A prospective randomised trial of a 'test and treat' policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999; 45: 186-90.
24. Jones R, Tait C, Sladen G, Weston-Baker J. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Clin Pract 1999; 53: 413-6.
25. McColl KE, Murray LS, Gillen D, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. Br Med J 2002; 324: 999-1002.
26. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 361-9.
27. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000; 321: 659-64.
28. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481-91.
29. Veldhuyzen van Zanten SJO, Chiba N, Armstrong D, et al. Efficacy of omeprazole (OME), ranitidine (RAN), cisapride (CIS) and placebo (PLA) in 512 Helicobacter pylori (Hp) negative primary care patients with uninvestigated dyspepsia (UD) - the CADET HN study. Gut 2001; 49(Suppl. III): A3364.
30. Stevens R, Baxter G. Benefit of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care. Gut 2001; 49(Suppl. II): A83(15/02).
31. Ladabaum U, Chey WD, Scheiman JM, Fendrick AM. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. Aliment Pharmacol Ther 2002; 16: 1491-501.
32. Makris N, Barkun AN, Fallone CA, Crott R, UBTAN Group. What is the most cost-effective strategy when managing young dyspeptic patients in the primary care setting? Int J Tech Ass Health Care 2003; 19: 442-60.
33. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 1270-85.